Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...
Multiple Sclerosis News Today

New biomarker may help identify MS patients for BTK inhibitors

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...
Pharmabiz

Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies

Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies: Rockville, Maryland Friday, January 9, ...
Oncology Nurse Advisor

Pirtobrutinib Approved for R/R CLL/SLL After Covalent BTK Therapy

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Targeted Oncology

The Top 5 Blood Cancer Advancements in 2025

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...